Mainline Biosciences, a polypeptide drug developer based in Zhongshan, has reportedly raised close to RMB 100 million (USD 13.8 million) in a Series A financing round. The round was led by Fuho Capital, with participation from Techsnow Capital and Dingfu Investment. The proceeds will be used to construct the company’s core technology platform and support clinical studies of its key product pipelines.
Company Profile and Pipeline
Founded in 2021, Mainline Biosciences has developed a series of Category 1 polypeptide drug candidates. The company’s lead candidate, MB1707, targets the CXCR4 receptor and is currently undergoing a Phase I clinical study in the US and Australia for cancer patients with high CXCR4 expression. This funding will accelerate the development of MB1707 and other pipeline products, positioning Mainline Biosciences at the forefront of innovative peptide drug development.-Fineline Info & Tech
